NCT06704347View on ClinicalTrials.gov

Safety Study of XT-150 in Participants With ALS

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
BIOLOGICAL

XT-150

XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).

Trial Locations (4)

21205

Johns Hopkins University, Baltimore

48202

Henry Ford Health, Detroit

85013

Barrow Neurological Institute (St. Joseph's), Phoenix

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Xalud Therapeutics, Inc.

INDUSTRY